短篇论著
ENGLISH ABSTRACT
中文版特应性皮炎控制工具的信效度与反应度的验证性研究
栾婷婷
彭承悦
宋晓婷
廖双璐
赵作涛
作者及单位信息
·
DOI: 10.3760/cma.j.cn112150-20221019-01007
Validation study of the Chinese version of atopic dermatitis control tool
Luan Tingting
Peng Chengyue
Song Xiaoting
Liao Shuanglu
Zhao Zuotao
Authors Info & Affiliations
Luan Tingting
Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China
Peking University School of Nursing, Beijing 100191, China
Peng Chengyue
Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China
Peking University School of Nursing, Beijing 100191, China
Song Xiaoting
Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China
Liao Shuanglu
Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China
Zhao Zuotao
Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China
·
DOI: 10.3760/cma.j.cn112150-20221019-01007
893
179
0
0
1
0
PDF下载
APP内阅读
摘要

为验证中文版特应性皮炎控制工具(atopic dermatitis control tool,ADCT)的信效度和反应度。本研究在获得中文版ADCT量表的授权后,采用便利抽样法,选取2022年10月于北京大学第一医院皮肤科就诊的114例特应性皮炎患者作为研究对象。使用一般资料调查表、中文版ADCT、患者湿疹自我测评量表(patient-oriented eczema measure,POEM)、峰值瘙痒数字评定量表(peak pruritus numerical rating scale,PP-NRS)、皮肤生活质量指数(dermatology life quality index,DLQI)和患者报告的疾病整体严重程度对患者进行调查。采用Mann-Whitney秩和检验和Spearman相关分析进行项目分析;采用内容效度指数(content validity index,CVI)评估内容效度;采用探索性因子分析评估结构效度;采用Cronbach′α系数评定内部一致性;采用Spearman相关分析评估ADCT与其他量表的相关性来评估外部反应度。结果显示,经项目分析保留所有条目。I-CVI为0.9~1,S-CVI/Average为0.983;经因子分析提取1个公因子,累计方差解释率为77.927%;量表Cronbach′α系数为0.937;中文版ADCT与POEM、PP-NRS、DLQI的相关系数分别为0.805、0.861、0.709。综上,中文版ADCT具有良好的信效度和反应度,适合测量评估中国特应性皮炎患者的疾病控制情况。

特应性皮炎;心理测定学;调查和问卷;疾病控制;信度;效度
ABSTRACT

To assess the reliability, validity and responsiveness of the Chinese version of the atopic dermatitis control tool (ADCT). After this study obtained authorization for the Chinese version of the ADCT scale. 114 patients with atopic dermatitis were enrolled from the Department of Dermatology, Peking University First Hospital using convenience sampling from October 2022. Patients were surveyed using the General Information Questionnaire, Chinese version of ADCT, patient-oriented eczema measure (POEM),peak pruritus numerical rating scale (PP-NRS),dermatology life quality index (DLQI) and the global patient self-assessment for disease severity. Mann-Whitney rank sum test and Spearman correlation analysis were used for item analysis; content validity was assessed using content validity index (CVI); exploratory factor analysis was used to assess structural validity; Cronbach′ alpha coefficient was used to assess internal consistency; Spearman correlation analysis was used to assess the correlation of ADCT with other scales to assess external responsiveness. The results showed that all items were retained by item analysis. I-CVI was 0.9-1, and S-CVI/Average was 0.983; the scale extracted one common factor by factor analysis, the cumulative variance explanation rate was 77.927%; the Cronbach′ alpha coefficient of the scale was 0.937; the correlation coefficients of the Chinese version of ADCT with POEM, PP-NRS, and DLQI were 0.805, 0.861, and 0.709 respectively. In conclusion, the Chinese version of the ADCT has adequate reliability, validity and responsiveness, and is suitable for measuring disease control in Chinese patients with atopic dermatitis.

Atopic dermatitis;Psychometrics;Surveys and questionnaires;Disease control;Reliability;Validity
Zhao Zuotao, Email: mocdef.3ab61oatoatouzoahz
引用本文

栾婷婷,彭承悦,宋晓婷,等. 中文版特应性皮炎控制工具的信效度与反应度的验证性研究[J]. 中华预防医学杂志,2023,57(03):422-426.

DOI:10.3760/cma.j.cn112150-20221019-01007

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
特应性皮炎(atopic dermatitis,AD)是一种以复发性湿疹样病变和剧烈瘙痒为特征的慢性炎症性皮肤病 1 , 2。儿童患病率为2.7%~20.1% 3,成人为2.1%~4.9%,女性发病高于男性 4。AD病程较长,反复迁延,给患者带来了较重的疾病负担 5。作为一种常见的慢性皮肤病,指南中指出当前疾病管理的目标是改善症状并建立长期控制 1 , 2。而目前被推荐用于评估疾病长期控制的工具是特应性皮炎控制工具(atopic dermatitis control tool,ADCT)或特应性湿疹回顾量表(recap of atopic eczema,RECAP) 6。其中ADCT使用较广 7 , 8,且在国外研究中显示出良好的信效度和反应度 9 , 10。虽然源量表作者提供了中文版ADCT,但是目前尚不清楚其在中国人群中的测量属性,故无法判断中文版ADCT是否适用于中国人群。因此,本研究将在中国AD人群中评估中文版ADCT的信效度和反应度以检验其是否能评估我国AD患者的疾病控制情况。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
中华医学会皮肤性病学分会免疫学组,特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81-88. DOI: 10.35541/cjd.20191000 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Wollenberg A , Christen-Zäch S , Taieb A ,et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children[J]. J Eur Acad Dermatol Venereol, 2020,34(12):2717-2744. DOI: 10.1111/jdv.16892 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Silverberg JI , Barbarot S , Gadkari A ,et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study[J]. Ann Allergy Asthma Immunol, 2021,126(4):417-428.e2. DOI: 10.1016/j.anai.2020.12.020 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Barbarot S , Auziere S , Gadkari A ,et al. Epidemiology of atopic dermatitis in adults: Results from an international survey[J]. Allergy, 2018,73(6):1284-1293. DOI: 10.1111/all.13401 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Laughter MR , Maymone MBC , Mashayekhi S ,et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017[J]. Br J Dermatol, 2021,184(2):304-309. DOI: 10.1111/bjd.19580 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Thomas KS , Apfelbacher CA , Chalmers JR ,et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting[J]. Br J Dermatol, 2021,185(1):139-146. DOI: 10.1111/bjd.19751 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
De Bruin-Weller M , Biedermann T , Bissonnette R ,et al. Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Th erapies [J]. Acta Derm Venereol, 2021,101(2):adv00402. DOI: 10.2340/00015555-3751 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
赵作涛,高兴华. 中重度特应性皮炎系统药物达标治疗专家指导建议[J]. 中国皮肤性病学杂志, 2022,36(8):855-864. DOI: 10.13735/j.cjdv.1001-7089.202205115 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Simpson E , Eckert L , Gadkari A ,et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis[J]. BMC Dermatol, 2019,19(1):15. DOI: 10.1186/s12895-019-0095-3 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Pariser DM , Simpson EL , Gadkari A ,et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)[J]. Curr Med Res Opin, 2020,36(3):367-376. DOI: 10.1080/03007995.2019.1699516 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
施月仙,张海明,黄亚琪,. 选择健康测量工具的共识标准(COSMIN)偏倚风险评价清单的解读[J]. 中国护理管理, 2021,21(7):1053-1057. 10.3969/j.issn.1672-1756.2021.07.018 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
中华医学会皮肤性病学分会免疫学组,特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81-88. DOI: 10.35541/cjd.20191000 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
吴明隆. SPSS 统计应用实务: 问卷分析与应用统计[M]. 重庆:重庆大学出版社, 2010:158-181.
[14]
孙昕霙. 健康调查问卷:设计原理与实践[M]. 北京:北京大学医学出版社, 2020:101-128.
[15]
王媛媛. 医学量表的编制与评价:理论、方法与实例操作[M]. 北京:北京大学医学出版社, 2020:116-117.
[16]
Stuart BL , Howells L , Pattinson RL ,et al. Measurement properties of patient-reported outcome measures for eczema control: a systematic review[J]. J Eur Acad Dermatol Venereol, 2021,35(10):1987-1993. DOI: 10.1111/jdv.17335 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
赵作涛,Email: mocdef.3ab61oatoatouzoahz
B
栾婷婷, 彭承悦, 宋晓婷, 等. 中文版特应性皮炎控制工具的信效度与反应度的验证性研究[J]. 中华预防医学杂志, 2023, 57(3): 422-426. DOI: 10.3760/cma.j.cn112150-20221019-01007.
C
所有作者声明无利益冲突
D
北京市科技计划课题 (Z211100007921017)
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号